Neuland Laboratories (524558) Q4 24/25 earnings summary

Executive summary

• FY25 total income was INR 1,497.3 crores, down 4.7% year-on-year, with Prime and Specialty segments as main contributors; topline and operating margins declined marginally, aligning with expectations.

• Management remains cautiously optimistic, expecting growth to resume in FY26, driven by new product commercialization, capacity expansion, and investments in the peptide segment.

• CMS revenues declined but showed strong traction from a broader customer base; molecules in the portfolio are at the take-off stage.

• Audited standalone and consolidated financial results for FY 2024-25 were approved with an unmodified opinion from statutory auditors.

• A final dividend of ₹12 per equity share was recommended for FY 2024-25, subject to shareholder approval.

Financial highlights

• FY25 total income was ₹1,497.3 crore, down 4.7% year-over-year; Q4 FY25 income was ₹335.8 crore, down 14% YoY.

• FY25 EBITDA was ₹342.8 crore (22.9% margin), down 27.8% YoY; Q4 FY25 EBITDA was ₹58.2 crore (17.3% margin), down 48.1% YoY.

• FY25 PAT was ₹259.4 crore, down 13.4% YoY; Q4 FY25 PAT was ₹27.7 crore, down 59% YoY; EPS at ₹202.2.

• Exceptional profit of ₹76.4 crore from transfer of investment property was recognized in FY25.

• Free cash flow for FY25 was ₹111 crore; net debt improved to negative ₹228.7 crore at FY25 end.

Outlook and guidance

• Growth expected to resume in FY26, with visibility from customer pipeline, new product launches, and commercial production from new Unit 3 block.

• Peptide segment investments and new capacity are anticipated to drive future opportunities.

• Management does not provide quantitative guidance but anticipates both CMS and GDS segments to grow, with CMS expected to recover more strongly.

• The Board recommended a final dividend and scheduled the 41st AGM for July 30, 2025.